About us

First-in-Class Breakthrough Treatment in Cardiogenic Shock

About Us Header Image

Our Vision

4TEEN4 Pharmaceuticals GmbH is developing Procizumab, an inhibitor of DPP3 pathway. A breakthrough, first-in-class Phase I asset with clinical proof of concept to restore cardiac function and prevent death due to Cardiogenic Shock an area of high social & economic burden with no effective therapy available.

Our Team

Advisory Board


Andreas Bergmann
Dr. Andreas Bergmann
Serial entrepreneur and former executive manager of AdrenomedAG and SphingotecGmbH, B•R•A•H•M•S (acquired by Thermo Fisher for 480m $). As an executive manager, Andreas raised 100m $ in equity financing for biotech companies in different st...
Karine Bourgeois
Dr. Karine Bourgeois
Our CSO Karine has 15+ years of experience in R&D of biotech companies. She is experienced in leading scientific, regulatory and drug production programs while directing cross-functional and multi-national teams. She established and current...
Mahir Karakas
Prof. Mahir Karakas
As CMO, Mahir is our link into medical practice. He holds the Professorship for translational research and innovative clinical trials at the University Medical Center Hamburg. He is a board-certified specialist for Cardiology, Intensive Car...
Kilian von Seldeneck
Dr. Kilian von Seldeneck
Kilian brings 10+ years of executive experience in financial and operational management across industries. As CFO, he takes care of our numbers. Having started his career in consulting and banking, he entered the biotech world via the M&A s...

Advisory Board

Renke Lührs
Renke Lührs (Chair)
Partner at BUSE and a member of the Corporate Law and M&A practice group
Christoph Springer
Dr. Christoph Springer
Chief Strategic Officer Vifor Pharma AG
Alexandre Mebazaa
Prof. Alexandre Mebazaa
Professor of Anesthesiology and Critical Care at Hospital Lariboisière, University
Gerald Möller
Gerald Möller
Former CEO of Boehringer Mannheim Group and former Head of Development and Strategic Marketing at Roche
Christoph Winterhalter
Dr. Christoph Winterhalter
Chief Business Officer at AGC biologics
Thomas Krause
Thomas Krause
Managing Director at Brandenburg Kapital GmbH
Laurent Kirsch
Laurent Kirsch
Chief Operating Officer Therabel Pharma
Marek Kozlowski
Dr. Marek Kozlowski
Senior Investment Director at NRW.Venture, Life Science Venture Capital arm of NRW.BANK

Shape your Future
Join our Team!

Career at 4TEEN4

4TEEN4 Pharmaceuticals is built on science, innovation, and dedication, where you can use your enthusiasm in changing patients’ lives and creating impact. We are a fast-growing, small-medium enterprise (SME) that grants our employees the ability to grow and shape their career pathways by developing an agile approach.

To achieve our goals, we need to promote our employees’ development.

At 4TEEN4, we offer a highly diverse environment
  • By enabling adaptability and promoting an outside-of-the-box way of thinking
  • With an established sense of belonging to ensure high engagement and a healthy workplace

Open Positions

Scientific Associate
Multi Project Manager (m_w_d) ─ Diagnostics (Dx)
Clinical Project Manager
Labormanager Pharmaforschung

Our company is continually looking for highly motivated professionals.
If you are interested in joining our innovative team, please contact us at career@4teen4.de.
Please see our applicant and candidate data protection.

Supported by

The project is funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Brandeburg Ministry for Labor, Social Affairs, Health, Women and Family (MASGF).

EFRE Logo go
Land Brandenburg Logo
Land Brandenburg Logo go
BSFZ Logo go